top of page


  • Hemophilia results from a missing or deficient protein needed for blood clotting. The two main forms are hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency).


  • Hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B.  The number of people with hemophilia in the United States is estimated to be about 20,000 individuals.


  • The worldwide incidence of hemophilia is not well known, but estimated at more than 400,000 people. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.


  • There is currently no cure for hemophilia. There are very effective treatments available in the US, but they may require lifelong infusion of expensive drugs that are manufactured from human plasma or through recombinant biotechnology.


  • Nearly 90% of Americans with severe hemophilia became infected with AIDS in the 1980s when blood and plasma donations in the US were not properly screened for HIV.


  • Improvements in donor screening and current viral inactivation measures in the commercial manufacturing process have made clotting factor products are very safe. CDC's blood safety surveillance system, in place since 1998, has found no reported cases of HIV or hepatitis infections associated with clotting factor products among hemophilia patients.  

bottom of page